Cancer Family
Malignant Bone Marrow Neoplasm
CI-CAN-00000226Explore in graph →
1,035 active trials28 approved drugs633 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000226Explore in graph →
Clinical trials
4,612 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (801)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01534260 | Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype | completed | Phase 1 / Phase 2 | 37 | Hamid SayarOTHER | 1 | Aug 17, 2018 | clinicaltrials |
| NCT02201329 | Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | completed | Phase 1 | 5 | Boehringer IngelheimINDUSTRY | 1 | Jul 30, 2018 |
| clinicaltrials |
| NCT01795924 | Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic Syndrome(AML/MDS) | terminated | Phase 1 / Phase 2 | 13 | Biosuccess Biotech Co., Ltd.INDUSTRY | 1 | Jul 24, 2018 | clinicaltrials |
| NCT01484015 | Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia | completed | Phase 1 | 70 | Wake Forest University Health SciencesOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT01517035 | Improving Blood Stem Cell Collection and Transplant Procedures | completed | Phase 1 / Phase 2 | 43 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT02226861 | Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation | completed | Phase 1 | 24 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT01768897 | CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 67 | Wake Forest University Health SciencesOTHER | 1 | Jul 3, 2018 | clinicaltrials |
| NCT02472626 | 6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 1 | Jul 3, 2018 | clinicaltrials |
| NCT01352650 | Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML) | completed | Phase 1 | 71 | Weill Medical College of Cornell UniversityOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT01050764 | Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells | terminated | Phase 1 / Phase 2 | 10 | Everett MeyerOTHER | 1 | Jun 27, 2018 | clinicaltrials |
| NCT00890929 | Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 45 | Stanford UniversityOTHER | 1 | Jun 18, 2018 | clinicaltrials |
| NCT02210858 | Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders | completed | Phase 1 / Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2018 | clinicaltrials |
| NCT02576301 | Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS(AML) | unknown | Phase 1 / Phase 2 | 105 | Mateon TherapeuticsINDUSTRY | 1 | Jun 4, 2018 | clinicaltrials |
| NCT02203825 | Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands | completed | Phase 1 | 12 | Celyad Oncology SAINDUSTRY | 1 | Jun 1, 2018 | clinicaltrials |
| NCT00660920 | Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies | completed | Phase 1 | 81 | Ariad PharmaceuticalsINDUSTRY | 1 | May 16, 2018 | clinicaltrials |
| NCT02635074 | Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 1 | 2 | Steven E. CoutreOTHER | 1 | May 14, 2018 | clinicaltrials |
| NCT02848248 | A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia | terminated | Phase 1 | 17 | Seagen Inc.INDUSTRY | 1 | May 14, 2018 | clinicaltrials |
| NCT02326584 | A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML | completed | Phase 1 | 116 | Seagen Inc.INDUSTRY | 1 | May 9, 2018 | clinicaltrials |
| NCT02905994 | Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | Massachusetts General HospitalOTHER | 1 | May 4, 2018 | clinicaltrials |
| NCT00626626 | Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation | terminated | Phase 1 / Phase 2 | 8 | Milton S. Hershey Medical CenterOTHER | 1 | Apr 25, 2018 | clinicaltrials |
| NCT02680951 | Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | Emory UniversityOTHER | 0 | Apr 19, 2018 | clinicaltrials |
| NCT01134120 | A Study in Myeloproliferative Disorders | completed | Phase 1 | 80 | Eli Lilly and CompanyINDUSTRY | 1 | Apr 17, 2018 | clinicaltrials |
| NCT01801046 | Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia | terminated | Phase 1 | 10 | University of Southern CaliforniaOTHER | 1 | Mar 30, 2018 | clinicaltrials |
| NCT01757639 | Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Mar 21, 2018 | clinicaltrials |
| NCT01451268 | Phase I/II Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)(PANOBEST) | unknown | Phase 1 / Phase 2 | 62 | Johann Wolfgang Goethe University HospitalOTHER | 1 | Mar 20, 2018 | clinicaltrials |
| NCT01798901 | AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia | completed | Phase 1 | 13 | Alison WalkerOTHER | 1 | Mar 14, 2018 | clinicaltrials |
| NCT00509899 | Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis | completed | Phase 1 / Phase 2 | 154 | Incyte CorporationINDUSTRY | 1 | Mar 12, 2018 | clinicaltrials |
| NCT02283190 | 1336GCC: Study of Erwinaze for Treatment of Acute Myeloid Leukemia (AML) | completed | Phase 1 | 5 | Ashkan EmadiOTHER | 1 | Mar 12, 2018 | clinicaltrials |
| NCT00602225 | Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 50 | University of WashingtonOTHER | 1 | Mar 9, 2018 | clinicaltrials |
| NCT01842139 | Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission | completed | Phase 1 | 7 | University of ChicagoOTHER | 1 | Mar 9, 2018 | clinicaltrials |
| NCT03347994 | Minnelide in Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | Justin WattsOTHER | 0 | Mar 6, 2018 | clinicaltrials |
| NCT02631252 | Phase I Study of Mitoxantrone and Etoposide Combined With Hydroxychloroquine, for Relapsed Acute Myelogenous Leukemia | terminated | Phase 1 | 1 | Alison Sehgal, MD, MSOTHER | 1 | Feb 23, 2018 | clinicaltrials |
| NCT00852709 | Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias(POE07-01) | terminated | Phase 1 | 35 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 2 | Feb 15, 2018 | clinicaltrials |
| NCT02856178 | Study on Safety and Pharmacokinetics of Intravenous F901318 for Fungal Prophylaxis in AML Patients(SAFEGUARD) | withdrawn | Phase 1 / Phase 2 | 0 | F2G LtdINDUSTRY | 0 | Feb 15, 2018 | clinicaltrials |
| NCT03036046 | Safety and Pharmacokinetics of Oral F901318 (Fluconazole and Posaconazole) IN Aml Leukaemia(SAFEGUARDFP) | withdrawn | Phase 1 / Phase 2 | 0 | F2G LtdINDUSTRY | 0 | Feb 15, 2018 | clinicaltrials |
| NCT02335814 | First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 1 | 51 | RAPT Therapeutics, Inc.INDUSTRY | 1 | Feb 9, 2018 | clinicaltrials |
| NCT01193699 | Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera(PEGINVERA) | completed | Phase 1 / Phase 2 | 24 | AOP Orphan Pharmaceuticals AGINDUSTRY | 1 | Jan 30, 2018 | clinicaltrials |
| NCT00875693 | A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML) | completed | Phase 1 | 47 | Weill Medical College of Cornell UniversityOTHER | 1 | Jan 17, 2018 | clinicaltrials |
| NCT00908167 | Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies | completed | Phase 1 | 44 | St. Jude Children's Research HospitalOTHER | 1 | Jan 12, 2018 | clinicaltrials |
| NCT00854646 | Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS) | completed | Phase 1 | 22 | Traws Pharma, Inc.INDUSTRY | 1 | Jan 10, 2018 | clinicaltrials |
| NCT00541866 | Safety and Tolerability Study of Voreloxin and Cytarabine Combination in Acute Myeloid Leukemia in Humans | completed | Phase 1 / Phase 2 | 110 | Sunesis PharmaceuticalsINDUSTRY | 1 | Jan 9, 2018 | clinicaltrials |
| NCT00583102 | Dose Escalation Phase I/II Study of Lovastatin With High-Dose Cytarabine for Refractory or Relapsed AML | terminated | Phase 1 / Phase 2 | 23 | University of IowaOTHER | 1 | Jan 5, 2018 | clinicaltrials |
| NCT01902329 | A Safety Study of SGN-CD33A in AML Patients | completed | Phase 1 | 195 | Seagen Inc.INDUSTRY | 1 | Jan 5, 2018 | clinicaltrials |
| NCT00295880 | Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer | terminated | Phase 1 / Phase 2 | 12 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Dec 28, 2017 | clinicaltrials |
| NCT00303667 | Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant | completed | Phase 1 / Phase 2 | 50 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00963872 | Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer | terminated | Phase 1 / Phase 2 | 31 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT02308761 | A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome | completed | Phase 1 | 26 | Hoffmann-La RocheINDUSTRY | 1 | Dec 11, 2017 | clinicaltrials |
| NCT02093403 | Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 25 | Bhavana BhatnagarOTHER | 1 | Dec 8, 2017 | clinicaltrials |
| NCT02049801 | MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 1 | 1 | Bruno C. MedeirosOTHER | 1 | Dec 6, 2017 | clinicaltrials |
| NCT03091933 | Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)(GLIDE) | unknown | Phase 1 / Phase 2 | 20 | Ciusss de L'Est de l'Île de MontréalOTHER | 1 | Dec 6, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Aug 17, 2018source: clinicaltrials